Current Investors

Promethera® is supported by experienced investors pioneering liver stem cell treatments

The company is committed to develop life-changing new cell therapies for patients suffering from serious liver diseases.

As an innovator in the emerging field of cell-based medicines, Promethera® is driven by the ambition of creating a diverse portfolio of drug candidates with partners and on our own account. This vision has attracted a broad range of European and Asian institutional and corporate investors throughout the Company’s development steps as a privately-held organization.


* Essentially HNWI and private investors

Promethera® has garnered the support of important investors that operate globally and spread accross three continents – Europe, North America and Asia.


  • Prof. Etienne Sokal
  • Sopartec-LTTO (UCLouvain Technology Transfer Office)